Mode
Text Size
Log in / Sign up
N/A N=47 Treatment

Study on OsseoSpeed™ Implants Replacing 2-5 Teeth in the Posterior Upper Jaw, Restored With Provisional Teeth Attached 6-7 Weeks Later

Jaw, Edentulous, Partially

Enrolled (actual)
47
Serious AEs
6.4%
Results posted
Feb 2014
Primary outcome: Primary: Implant Survival Rate — 96.25 percentage of implants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
OsseoSpeed™ (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Dentsply Sirona Implants and Consumables
Primary completion
Sep 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Implant Survival Rate
96.25
PRIMARY
Implant Stability
68.3
PRIMARY
Marginal Bone Adaptation
0.3

Summary

The purpose of the study is to evaluate Astra Tech Dental Implant System, Fixture Osseospeed™, in patients with tooth loss in the posterior maxilla in an early loading protocol. Primary objectives are implant stability, marginal bone adaptation and survival rate.

Eligibility Criteria

Inclusion Criteria

  • Provision of written informed consent
  • 18 years of age and over
  • Edentulous in the posterior maxilla, Kennedy classes I or II. Last natural tooth, or previously restored implant in function is canine or first bicuspid.
  • Deemed by the investigator as likely to present an initially stabile implant situation suitable for early loading

Exclusion Criteria

  • Untreated caries and/or periodontal disease of residual dentition
  • History of edentulism in the area of implant placement of less than two months
  • Current need for pre-surgical bone or soft tissue augmentation in the planned implant area.
  • History of pre-surgical bone or soft tissue augmentation, within12 months, in the planned implant area.
  • Sinus floor thickness of less than 5 mm, verified by periapical radiographs.
  • Any systemic or local disease or condition that would compromise post-operative healing and/or osseointegration
  • Need for systemic corticosteroids or any other medication that would compromise post-operative healing and/or osseointegration
  • Present alcohol or drug abuse
  • Unable or unwilling to return for follow-up visits for a period of 5 years
  • Current use of smoking tobacco
  • Pregnancy or lactation at the time of enrollment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00711113). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search